Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Anagnostics Enters Sales Cooperation with Analis S.A.

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
Company enters cooperation for Belgium and Luxembourg.

The Belgian company is specialized on clinical diagnostics and distributes Anagnostics’ innovative laboratory in the areas of drugs of abuse screening, personalized medicine (oncology) and sepsis diagnostics.

Since this summer Analis S.A. from Suarlée (near Namur) offers Anagnostics’ diagnostic products for drugs of abuse screening and personalized medicine.

In the coming months the sales portfolio will be enlarged by tests supporting the diagnosis and therapy of sepsis.

Analis and Anagnostics aim to serve hospitals in the Belux countries by offering truly innovative products and first class service.

“Analis is specialized on clinical diagnostics for a broad and loyal customer base and emphasizes first class support and advice of customers. Therewith Analis is the ideal partner for the distribution of our laboratory tests in Belgium and Luxembourg”, comments Christoph Reschreiter, CEO of Anagnostics Bioanalysis GmbH.

Guy Stukkens, CEO of Analis S.A. is looking forward to the sales cooperation: “We clearly see the trend towards more specific as well as more targeted and faster diagnostics, which is offered by multiplexed diagnostics. Anagnostics reacted on this need perfectly well. With the hyborg device and the test portfolio Anagnostics offers good market opportunities. The fast and efficient testing of drugs of abuse consumption ensures access to therapy institutions. The simple and highly sensitive tests in personalized medicine are particularly advantageous for small and medium sized pathologies, because cost efficiency is ensured even with low sample numbers.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Anagnostics and Molzym Form Strategic Alliance Fighting Sepsis
Agreement and partnership to commonly develop hybcell Pathogens DNA.
Monday, July 09, 2012
Ramcon A/S (Denmark) Distributes and Supports Anagnostics Products
Ramcon covers the Northern European countries and serves customers in Denmark, Sweden, Norway, Finland and Iceland with a highly specialized sales force.
Thursday, April 12, 2012
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos